Flupentixol

Evidence Level: L5

Predicted Indications: 9

Flupentixol

Pharmacist Assessment Report

Flupentixol: Retinal dystrophy with or without extraocular anomalies

One-Sentence Summary

Flupentixol is an antipsychotic originally used to treat schizophrenia. The TxGNN model predicts it may be effective for retinal dystrophy with or without extraocular anomalies, but there are currently 0 clinical trials and 0 publications supporting this prediction, so it rests on the model score alone.

Quick Overview

Item	Content
Original Indication	Not recorded in the local data
Predicted New Indication	Retinal dystrophy with or without extraocular anomalies
TxGNN Prediction Score	0.9999
Evidence Level	L5
Australia Market Status	Listed on the PBS Schedule (1 of 1 items) – TGA (ARTG) registration status is not included in this data
Number of PBS Items	1 (valid: 1)
Recommended Decision	Hold

Why is This Prediction Reasonable?

Currently, detailed mechanism of action data is not available in the data compiled for this report. Flupentixol is generally known as a dopamine receptor antagonist. The pharmacology data compiled lists binding to the D1, D2, D3 and D5 receptors. Its efficacy in schizophrenia is established, but there is no data showing how this would apply to the predicted indication.

On the available data, no mechanistic link to retinal dystrophy is supported. Inherited retinal dystrophies are genetically driven, and there is no evident rationale for an antipsychotic to change the course of disease. The very high TxGNN score (0.9999, rank 477) is a TxGNN model (deep learning) prediction only, with no clinical trial or literature behind it. It should be treated as a hypothesis-generating signal, not as evidence of benefit.

Other predictions for this drug (all L5, all Hold) include Charcot-Marie-Tooth disease type 1G, a congenital disorder of glycosylation, perisylvian polymicrogyria, hydranencephaly, several forms of myopia and atypical glycine encephalopathy. None has trial or literature support. The myopia predictions have a speculative link through dopaminergic signalling in eye growth, but nothing in the data compiled for this report substantiates it.

Clinical Trial Evidence

Currently no related clinical trials registered.

Literature Evidence

Currently no related literature available.

Australia Market Information

ARTG Number	Product Name	Dosage Form	Approved Indication
ARTG 2255Q	Fluanxol Depot	Oily I.M. injection 20 mg in 1 mL	Not available in the data compiled

Cytotoxicity

Flupentixol is not an antineoplastic drug, so this section does not apply.

Safety Considerations

Drug Interactions: The interaction query completed, but it returned only pharmacological target bindings (dopamine D1, D2, D3 and D5 receptors), not drug-drug interactions with graded severity. These are consistent with its antipsychotic action. No specific interacting drugs were identified.

Please refer to the TGA-approved Product Information (PI) for warnings and contraindications.

Conclusion and Next Steps

Decision: Hold

Rationale: The prediction is supported only by the TxGNN score. There are no clinical trials or publications, the mechanism of action is not available, and there is no plausible biological rationale for an antipsychotic in a genetically driven retinal dystrophy. Evidence is at the lowest level (L5).

To proceed, the following is needed:

Mechanism of action data (for example from DrugBank) and a documented mechanistic link to retinal dystrophy
Preclinical or in vitro evidence in a relevant retinal disease model
Product Information warnings and contraindications for the Australian product, which are needed before any safety screening
Approved indication text and manufacturer details for the ARTG entry
A literature and trial registry search (including ANZCTR) for any relevant studies
Disclaimer

This content is for research purposes only and does not constitute medical advice. Clinical validation is required before any clinical application.